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Many multiple testing procedures (MTP) have been developed in recent years. Among
these new procedures, the graphical approach is flexible and easy to communicate with
non-statisticians. A hypothetical Phase III clinical trial design is introduced in this manuscript
to demonstrate how graphical approach can be applied in clinical product development. In
this design, an active comparator is used. It is thought that this test drug under devel-
opment could potentially be superior to this comparator. For comparison of efficacy, the
primary endpoint is well established and widely accepted by regulatory agencies. How-
ever, an important secondary endpoint based on Phase II findings looks very promising.
The target dose may have a good opportunity to deliver superiority to the comparator. Fur-
thermore, a lower dose is included in case the target dose may demonstrate potential
safety concerns. This Phase III study is designed as a non-inferiority trial with two doses,
and two endpoints.This manuscript will illustrate how graphical approach is applied to this
design in handling multiple testing issues.
Keywords: multiple testing procedures, non-inferiority, dose selection, multiple endpoints, superiority and non-
inferiority
INTRODUCTION
There has been a rapid development in multiple testing proce-
dures (MTP) in the past 10 years. Numerous of new procedures
have been proposed to deal with not only multiple testing prob-
lems with single source of multiplicity, but also more complex
multiple testing problems involving more than one source of mul-
tiplicity. For example, the presence of multiple endpoints, multiple
dose regimens, non-inferiority and superiority tests, and multiple
region or patient populations.
To meet the demand of more complex trial design and strong
control of family-wise error rate, several papers have been pub-
lished in recent years to construct powerful yet flexible MTP. For
a summary of recent question and development in multiplicity
issues, one can refer to Hung and Wang (1) and Wang and Cui (2).
In many cases, the need to design a complex trial is inevitable.
In this paper, we use a hypothetical phase III design to illustrate
several statistical considerations in the designing stage of a con-
firmatory phase III trial. This discussion will include but not
limited to selection of non-inferiority margin, determination of
primary and secondary endpoints, dose selection, and multiplic-
ity adjustment. We hope to use this case study to show the flow of
statistical thinking in trial design and how to coordinate different
requirements from different functions of a trial team.
More importantly, we also want to use this example to show
how to use currently available tools to design flexible MTP that
can fit one’s need and the caveat in choosing an MTP.
A HYPOTHETICAL PHASE III CLINICAL TRIAL DESIGN
After the encouraging Phase II results are obtained from a drug
candidate, the project team decided to progress it for Phase III
development. The underlying disease is a difficult condition, and
there was only one approved drug on the market. For Phase III
study design, it is not ethical to conduct a placebo-controlled trial.
Hence the Phase III program would have to be a non-inferiority
trial designed to compare with the active control. For this indica-
tion, the primary endpoint is well established and widely accepted
by regulatory agencies. In order to use this primary endpoint to
design a non-inferiority trial, it is critically important to calculate
the non-inferiority margin for this comparison. Such a margin will
have to be agreed between the sponsor and the regulatory agencies,
before the trial design can be finalized.
Based on the Phase II findings, a different endpoint demon-
strates promising results. The project team considers this endpoint
could distinguish the study drug from the active control, and other
potential competitors which may be introduced to the market in
some future time. On this basis, this endpoint needs to be included
in the Phase III design as a key secondary endpoint. The hope is
that if the primary endpoint demonstrates non-inferiority to the
active control, meanwhile, this secondary endpoint could show
superiority, then the study drug can be marketed with a strong
label. A drug label contains important efficacy and safety infor-
mation to assist physicians in prescribing the drug. Information
contained in the drug label (3) informs patients regarding appro-
priate drug use and potential adverse effects. The drug label is
finalized after a new drug completes the pre-marketing develop-
ment process but at the time it receives regulatory approval and
is ready for general patient population use. The sponsor and the
regulatory agency (e.g., FDA) agree upon the content of the label.
If the sponsor hopes to promote the study drug using a secondary
endpoint, it is important for this secondary endpoint to be α-
protected so that it could be included in the drug label if statistical
significance can be observed.
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For this development program, a target dose was selected based
on all of the early findings including non-clinical and clinical Phase
I and II data. This target dose is used in the Phase III study design
to be compared with the active control. However, the project team
also considered the risk that there might be late stage adverse events
that may cause safety concerns at the target dose. Hence a lower
dose was introduced and this study becomes a three-arm design –
target dose of the study drug, lower dose of the study drug, and
the active control.
Both the primary and the secondary endpoints are con-
tinuous variables calculated as change from baseline to the
designed study time point. The distributions of residuals from
both variables appear to follow normal distribution. Given
the large sample size needed for the Phase III study, a lin-
ear model is proposed to analyze these endpoints. For both
endpoints, a reduction from baseline indicates clinical improve-
ment. Hence the clinical efficacy can be achieved in a placebo-
controlled study if the mean treatment difference is negative,
clinically meaningful, and statistically significant. For an active-
controlled trial, efficacy can be achieved if the upper limit of the
95% confidence interval for mean difference (test drug subtract
active control) does not exceed the pre-specified non-inferiority
margin.
Given this three treatment group design, the project team hopes
that the target dose will deliver clinical superiority to the active
control (in the primary endpoint), and the lower dose will deliver
at least non-inferiority in efficacy. If the safety profile for the tar-
get dose is acceptable, then the sponsor will market the study drug
at the target dose. However, in case there is safety concern from
the target dose, then if the low dose is relatively safe, and with
non-inferiority in efficacy, this lower dose can be delivered to the
general patient population.
For the secondary endpoint, a minimally clinically important
difference (MCID) can be established using treatment differ-
ence of change from baseline to the specific time point. The
difference is based on mean outcome of test drug subtract
mean outcome of active control, and a negative value means
treatment improvement. The project team expected that clini-
cal superiority can be observed in the comparison of target dose
against active control and also in the comparison of lower dose
against the active control. Sample size calculation using the sec-
ondary endpoint is based on the known standard deviation, and
this MCID.
STATISTICAL CONSIDERATIONS
Given this background, there are several statistical considerations
for this Phase III study design – issues relating to non-inferiority,
dose selection, and multiple endpoints. These issues are presented
in more details below.
In order to establish the non-inferiority margin, previous com-
parative studies including both placebo and the active compara-
tor were used. It would be helpful to review the existing data
from these historical clinical trials, and obtain an estimate of
treatment difference (of active comparator against placebo) from
the combined data across these studies. The project team first
identified those studies from literature, then a meta-analysis was
performed on these studies. In each of the historical study, the
efficacy measurements from the primary endpoint are obtained
both from the placebo group, and from the active comparator. A
meta-analysis with random-effect model was performed on these
measurements and a 95% confidence interval was constructed on
the mean treatment difference between the active comparator and
the placebo.
The primary endpoint is a continuous variable, and negative
value of change from baseline indicates improvement in efficacy.
On this basis, the treatment difference of comparator mean sub-
tracting placebo mean is a negative number. According to the
95–95 rule, in order to preserve 50% of treatment effect, the mid-
dle point (50% to the left of the lower confidence limit from the
placebo mean) between the active control mean and the lower con-
fidence limit is chosen as the non-inferiority margin – see Figure 1
(Step A).
The thinking process goes from the placebo mean (A), to the
point B, where B is obtained from the calculation of 95% confi-
dence interval on differences between active control and placebo.
Then apply this confidence interval on the point A. Next to look
at C, which is the mean of active control. Finally a non-inferiority
margin D is selected. Suppose the interest is to preserve 67% (2/3)
of treatment benefit, then D should be chosen to be 67% lower
from B, or 33% above C. This means that for the Phase III study
the mean difference of study drug effect subtract the active com-
parator effect is expected to have a negative value, and the upper
limit of the corresponding 95% confidence interval should not
exceed this non-inferiority margin.
The determination of such a margin should be based on
extensive discussions with regulatory agencies. Only after the
agreement is reached between the sponsor and the regulatory
FIGURE 1 | Non-inferiority margin.
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agencies, such a margin can then be used for the Phase III study
design. Sample size calculation will be based on this margin. From
Figure 1 (Steps B and C), the upper limit of 95% confidence inter-
val – denoted as “)“ for the treatment difference (mean of study
drug subtract mean of active control) needs to be below (to the left
of) the margin (D−C) in order to claim non-inferiority. Of course,
for superiority, the upper confidence limit should be below 0.
In a typical clinical development program, dose selection takes
place during the Phase II development stage. However, in many
clinical development programs, even with an extended Phase II
exploration, often times only a range of active doses can be
considered for Phase III confirmation. It is very rare that only
one specific fixed dose is confidently proposed to bring into
the Phase III development. Usually only a single target dose is
suggested for the Phase III program. However, in many Phase
III designs, a dose that is higher, or lower than the target dose
(in some cases one higher dose and one lower dose are both
included) is also tested. Sometimes both a higher dose, and a
lower dose, in addition to the target dose are used in the Phase
III development.
From drug label point of view, each approved dose for the
study drug needs to be efficacious, and safe. Hence a given dose
can only be approved if the benefit outweighs the risk. The project
team hopes that the target dose will deliver an acceptable safety
profile, and that both the primary and the secondary endpoint
can demonstrate superiority to the active control. However, if
the long-term safety events observed from the target dose is not
as good as expected, then the lower dose is expected to serve
as a backup. The lower dose is considered to be relatively safe,
with superiority on the secondary endpoint, but may possibly
only deliver non-inferiority to active control on the primary end-
point. Based on power calculation, the sample size to be used
for demonstration of non-inferiority of the primary endpoint is
sufficiently large to also provide good power for the secondary
endpoint to show superiority. Therefore, sample size is calculated
using the non-inferiority margin pre-specified for the primary
endpoint.
From above discussion, it is clear that in order to control the
Type I error (α), under non-inferiority, dose selection, and mul-
tiple endpoint issues, the major statistical concern in this study
design is the MTP. The section below focuses on such a discussion.
MULTIPLE TESTING PROCEDURES
In designing a MTP for the program, it is all about how to
assign and “recycle” the significance level. The idea of recycle has
been applied in several MTP in the literature, such as the Holm
procedure and Fallback procedure, etc. In the case of two null
hypotheses, a procedure allowing recycle of the significance level
will test one null hypothesis at α/2 and the other hypothesis at α if
the first one has been rejected. This is improvement over the Bon-
ferroni procedure which will test both hypotheses at α/2. This idea
is viewed as recycling the significance level of α/2 after rejecting
the first hypothesis.
In this specific drug development program, non-inferiority of
the primary endpoint is in the first hierarchy of a sequence of
hypotheses. Upon proving non-inferiority of the primary end-
point, the project team can either test the superiority of the
secondary endpoint or pursue superiority for the primary end-
point. However, as discussed above, the two directions are both
logically sound. Hung and Wang (1) argued that in this case the
superiority of primary endpoint and secondary endpoint should
be tested simultaneously and a MTP should be carefully designed
to control the family-wise error rate.
First we design a tree-structured gatekeeping procedure for this
case. There are in total six null hypotheses of interest as listed
below:
• H1: high dose is inferior to active control in primary endpoint
• H2: low dose is inferior to active control in primary endpoint
• H3: high dose is not superior to active control in primary
endpoint
• H4: high dose is not superior to active control in secondary
endpoint
• H5: low dose is not superior to active control in primary
endpoint
• H6: low dose is not superior to active control in secondary
endpoint
Two families should be considered in the current setting, which
are F1= {H1, H2} and F2= {H3, H4, H5, H6}. The first family F1
should be tested first. The second family F2 will be tested only if at
least one rejection is observed in the first family. More specifically,
we test H3 and H4 if and only if H1 is rejected, while H5 and H6
are tested if and only if H2 is rejected.
Gatekeeping procedure will test H1 and H2 as if no further fam-
ilies of hypotheses are of interest. Using Bonferroni adjustment,
this requirement means the full α will be split between H1 and
H2, usually α/2 for each when we weigh H1 and H2 equally. Upon
showing significant result for H1, the significant level α/2 will then
be passed to H3 and H4. Assuming equal weighting again, this α/2
will be split to α/4 for each of H3 and H4. The same procedure will
be applied to H2, H5, and H6.
If one wishes to use a more powerful method such as Hochberg,
it can be done for the second family among H3 and H4 (or H5 and
H6). Instead of equally splitting α/2 between H3 and H4, one can
compare the larger p-value of H3 and H4 with α/2 and reject both
of the hypotheses if p-value <α/2. Otherwise compare the smaller
p-value with α/4 and reject only the corresponding hypothesis
with smaller p-value. However, the Hochberg procedure cannot be
applied to the first family directly as it is “non-separable” accord-
ing to Dmitrienko and Tamhane (4) and a truncated version of
Hochberg procedure is recommended. On the other hand, the
multistage and mixture parallel gatekeeping procedures proposed
in the same paper does not work for this specific example because
{H1, H2} is not a parallel set for the secondary family of hypotheses.
It is essential to know how much significant level can be passed
from H1 to H3 and H4, and how much can be passed from H2 to H5
and H6. These two sets of significant levels are separate and can-
not be shared between the two paths with regular tree-structured
gatekeeping procedure.
This tree-structured gatekeeping procedure assuming equal
weighting can be visualized in Figure 2 using the new graphi-
cal representation proposed by Bretz et al. (5). R package “gMCP”
is developed to implement the graphical approach which provides
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a graphical user interface. In this manuscript, we refer to the orig-
inal paper by Bretz et al. (5) and use their R package to create the
visualization of all examples. Interested readers can also reproduce
the graphical approach steps for each example introduced in this
manuscript and follow the dynamic illustration provided by the
“gMCP” package.
Figure 2 indicates that at the very first step, the significant level
α is split equally among H1 and H2. After this step, each part is
bound with the significant level assigned. In case one path fails to
show significance (for example, H2 is retained), the part of signif-
icant level assigned to that path is consumed. The arrows in the
graph show how significant level will be shifted from one node
to another given the hypothesis in the starting node is rejected at
the assigned level. The weight on the arrow tells how much of the
significant level in the starting node will go to the next node. In
this example, H1 is originally assigned with significant level α/2. If
H1 is rejected at α/2, then one half of the α/2 will be given to H3
and the other half to H4. Since H3 and H4 originally did not get
any significant level assigned, they will both be tested at α/4 which
comes from splitting the α/2 from H1. In the next step, if H3 is
rejected at level α/4, then all of the value α/4 will be passed to H4
(and vise versa). Whether H3 or H4 should be tested first depends
on their p-values. For more details on the graphical representation,
we refer to the original paper by Bretz et al. (5). From this point
on, we assume the readers have some familiarity to the graphical
approach and can understand the graphical terminologies.
What worth to point out is that the tree-structured gatekeeping
have two separate and independent paths, i.e., {H1, H3, and H4}
and {H2, H5, and H6}. No significance level can be “recycled” and
reassigned between the two paths. Intuitively, we should be able
to test H2 at full α given H1 is rejected at α/2 as Holm’s procedure
suggests. However, by adding the secondary family of hypotheses,
this path is closed and H2 has to be tested at α/2 even though all
of H1, H3, and H4 are rejected.
This observation roots in the principle that is used when con-
structing gatekeeping procedures, which is the testing result of
secondary endpoints cannot affect the test on primary endpoints.
The gatekeeping procedure (6) implemented this principle by
not allowing reuse of the significant level from one path on the
other paths. Their rationale is such reallocation will cause the low
dose primary endpoint hypothesis H2 tested with an alpha level
that depends on the testing result of high dose secondary family
hypotheses (H4 and/or H3). On the other hand, there has been
several publications suggest a different opinion that the principle
should be restricted only within fixed dose level. Specifically, the
testing result of H2 should not be affected by the test on H5 and
H6 (all in the low dose path), but might benefit from rejection of
both H3 and H4 (from high dose). Interested readers can refer to
Wang and Cui (2) for a summary.
This new implementation allows us to test H2 at full α level if
high dose shows efficacious on both endpoints (rejection of H1,
H3, and H4), which is more powerful than the original gatekeeping
procedure. The graphical representation of this implementation is
illustrated in Figure 3.
In this procedure, all of the significant level α/2 assigned to the
high dose path can be reused in low dose path if all H1, H3, and
FIGURE 2 | Gatekeeping procedure.
FIGURE 3 | Reuse alpha among dose levels.
H4 are rejected. Even if only one of H3 or H4 is rejected along with
H1, one eighth of α can be reused in low dose path.
Note that this approach also allows the project team to assign
different initial significant levels to H1 and H2. For example, if the
high dose is of more interest, the project team can assign three
quarters of α to H1 instead of α/2 and only one quarter of α to
H2. Since the trial will be powered to show significance at 3α/4 for
H1, it is very likely that H2 will be tested at α with the recycled
significant level from H1. Also in this way, the team is on the safe
side to have a positive trial than testing H1 at α/2 level.
Users need to be careful writing their programs since this graph-
ical approach is not yet supported in regular tree-structured gate-
keeping procedure SAS macro. The graphical approach R package
“gMCP” is recommended.
EXAMPLE
To better understand how the MTP worked, we consider a spe-
cific artificial scenario of the active-controlled trial with two doses
and two endpoints example with several different approaches and
discuss their difference in findings. The significant level is fixed at
two-sided level 0.05.
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Suppose the following raw p-values are observed for each null
hypothesis:
• p1= 0.005 for H1: high dose is inferior to active control in
primary endpoint
• p2= 0.027 for H2: low dose is inferior to active control in
primary endpoint
• p3= 0.020 for H3: high dose is not superior to active control in
primary endpoint
• p4= 0.009 for H4: high dose is not superior to active control in
secondary endpoint
• p5= 0.133 for H5: low dose is not superior to active control in
primary endpoint
• p6= 0.018 for H6: low dose is not superior to active control in
secondary endpoint
First we apply the gatekeeping procedure. Since α will be split
among H1 and H2, each will be tested at level α/2= 0.025. In
the first step, H1 is rejected and the significant level α/2 can be
used again among H3 and H4. Since H2 is not rejected, no further
test will be performed on H5 and H6 and the significant level of
α/2 on H2 is consumed. In the second step, we test H3 and H4.
If using the Bonferroni–Holm method, we follow the order that
p4 < α/4= 0.0125 and p3 < α/2= 0.025, thus both H3 and H4 are
rejected. If the Hochberg method is used, we reject both of them
directed by comparing p3 < α/2= 0.025.
As we mentioned before, even the high dose group shows sig-
nificance in all hypotheses, the significant level in this family (H1,
H3, and H4) cannot be reused by the low dose group. Thus, none
of the low dose hypotheses are rejected by gatekeeping procedure.
The testing result is summarized in Table 1.
To overcome the limitation of gatekeeping procedure, several
authors have recommended to reuse significant level across dif-
ferent dose levels. Thanks to the flexibility of graphical approach,
this idea can be specified as Figure 3. Now we explore how we can
benefit from recycling the significant level. At the first step, H1 and
H2 are of consideration and we start from the one with smaller
p-value, which will be H1 in our case (marked in dark color). Since
p1 < α/2= 0.025, H1 will be rejected and its assigned significant
level will be split among H3 and H4, each getting α/4= 0.0125.
Then we test H4 because p4 is smaller and reject it as p4 < α/4. The
significant level used on H4 will then be split in half to H3 and
H2, each getting α/8. This splitting results in overall 3α/8 on H3
and 5α/8 on H2. At this stage, whether H3 or H2 should be tested
first depends on the ratio of p3/(3α/8) and p2/(5α/8), whichever is
smaller. According to the observed p-values, p2/(5α/8) is smaller
and H2 will be tested and rejected first. Then we move our attention
from H2 to H5 and H6 and come back to H3 later. The signif-
icant level 5α/8 on H2 will be split to H5 and H6, each getting
5α/16. H6 with a smaller p-value will be tested first. However,
since p6 > 5α/16= 0.016, we fail to reject H6 or H5 and consumed
the significant level on them. At the final step, we test H3 with the
significant level 3α/8 assigned to it. Since p3 > 3α/8= 0.019, we
fail to reject H3 and conclude the whole process.
This procedure also ends up rejecting three out of six hypothe-
ses, which is summarized in Table 1. One might argue that it is
no better than the original gatekeeping procedure as we cannot
Table 1 |Testing result of gatekeeping procedure and the two modified
graphical approaches.
Gatekeeping Figure 3 Figure 4
H1 Reject Reject Reject
H2 Reject Reject
H3 Reject Reject
H4 Reject Reject Reject
H5
H6 Reject
quantify which hypothesis is of more importance and suggest the
rejection of H2 is more important than the rejection of H3. One
may also argue that, there is too much weight shifted to H2 after H4
is rejected. In practice, it makes more sense to complete one path
H1→ (H3 and H4) of the high dose before splitting too much
alpha to the other path. In fact, it is quite arbitrary to pass one
half of the significance level from H3 to H2 and H4 (or H4 to H2
and H3).
Alternatively, we present a better design in Figure 4 using
the concept of infinitesimal small weight. Assume the trial team
believes it is of more interest to show positive result in all high dose
hypotheses (among H1, H3, and H4) before moving on to the low
dose. An infinitesimal small weight epsilon edge can be assigned
from H3 to H2 and H4 to H2.
Different from the procedure in Figure 3, after H4 is rejected
at the second step, almost all of its significance level (except
an infinitesimal amount) will be assigned to H3. Then H3 will
be tested at level almost equal to α/2, which will be rejected as
p3= 0.020< α/2. Then the significance level of α/2 will be passed
to H2, adding to its original α/2 assigned at the beginning of the
process. Next step H2 will be tested at level alpha and rejected since
p2= 0.027. H5 and H6 will receive α/2 each upon the rejection of
H2. Eventually, H6 will be rejected and H5 retained. Overall, the
procedure utilizing infinitesimal edge will have five null hypothesis
rejected as summarized in Table 1.
Similarly, if it is more important to show both high dose and
low dose are non-inferior at the primary endpoint (H1 and H2),
one can add direct edge between H1 and H2 while replacing the
rest of the edges with infinitesimal weight as shown in Figure 5.
The graphical approach is flexible enough to adjust according to
different requirement in clinical research.
It is also worth to point out that when there is a tie in the
p-values, the graphical approach will always reach the same con-
clusion regardless which hypothesis involved in the tie will be
tested and rejected first. In theory the probability to observe exactly
equal p-values from two independent tests is 0, we do quite often in
practice seep-values<0.0001 being reported in statistical software.
The proof that graphical approach is robust with tied p-values can
be found in Bretz et al. (7).
DISCUSSION
In clinical development of new medicinal products, alpha pro-
tection is one of the most important statistical tasks. The drug
approvals and the go/no-go decisions are all based on the fact
that the experiment-wise Type I error (alpha) not being inflated.
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FIGURE 4 | Infinitesimal small weight edge at H3 (H4)TO H2.
FIGURE 5 | Direct path between H1 and H2.
When there are multiple treatment groups, multiple endpoints, or
multiple objectives in a clinical trial, the pre-specification of MTP
becomes a very important statistical practice in study design.
The process of designing a Phase III clinical trial involves
in many discussions among team members – statisticians, clin-
icians, regulatory affairs, marketing, medical affairs – and their
corresponding line management as well as the upper manage-
ment within the sponsor. In many situations, the protocol may
even be sent to FDA and/or other regulatory agencies to seek for
their input. At this point, choice of the MTP strategy is critical
in addressing the primary and secondary objectives under the
given study design assumptions. Different assumptions made dur-
ing this stage will have different implications after the data read
out. Therefore, various MTP strategies need to be communicated
clearly from the statisticians to other team members and the upper
management, benefits and risks of each strategy need to be fully
discussed before a final set of multiple comparison adjustments
can be selected.
This manuscript covers statistical considerations in designing a
Phase III active-controlled trial with two doses and two endpoints.
Here we present the selection of MTP under three challenges:
non-inferiority/superiority testing, multiple doses and multiple
endpoints. An example is introduced here. This hypothetical, prac-
tical example covers the gatekeeping and the graphic approaches
to deal with these challenges. As can be found from this example,
various assumptions or various priorities of objectives can lead
to various MTP strategies. From a statistical application point of
view, we hope to make the proposal to be flexible so that the statis-
tical method can be applied to a wide range of situations in solving
real world problems.
These approaches, as well as the thinking behind them, can
be generalized to cases where there are more than two doses or
more than two endpoints or both. Furthermore, when a case that
is simpler than this setting is proposed as when only one or two
of the three (non-inferiority, multiple doses, multiple endpoints)
challenges appear, the thinking behind our proposal can still be
applicable. Although the situation is derived from a continuous
variable which serves as the primary and secondary endpoints, the
discussion covered in this manuscript can also be applied to binary
data, count data, or time-to-event data.
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